uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
23.87
+0.90 (3.92%)
At close: Nov 3, 2026, 4:00 PM EST
23.10
-0.77 (-3.23%)
After-hours: Nov 3, 2026, 7:30 PM EST
uniQure Employees
uniQure had 221 employees as of December 31, 2025. The number of employees increased by 12 or 5.74% compared to the previous year. That makes uniQure the 26,044th largest employer in the world and 3,318th in the United States.
Employees
221
Change (1Y)
12
Growth (1Y)
5.74%
Revenue / Employee
$84,489
Profits / Employee
-$1,141,217
Market Cap
1.66B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 221 | 12 | 5.74% |
| Dec 31, 2024 | 209 | -271 | -56.46% |
| Dec 31, 2023 | 480 | -21 | -4.19% |
| Dec 31, 2022 | 501 | 38 | 8.21% |
| Dec 31, 2021 | 463 | 131 | 39.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Novavax | 749 |
| Immunocore Holdings | 524 |
| Intellia Therapeutics | 377 |
| Nuvation Bio | 305 |
| UroGen Pharma | 300 |
| Innoviva | 159 |
| Maze Therapeutics | 141 |
QURE News
- 1 day ago - uniQure announces FDA acceptance, priority review for ifezuntirgene inilparvovec - TheFly
- 1 day ago - uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington's Disease - GlobeNewsWire
- 6 days ago - uniQure to Announce Third Quarter 2026 Financial Results - GlobeNewsWire
- 20 days ago - uniQure assumed with a Buy at UBS - TheFly
- 4 weeks ago - uniQure downgraded to Equal Weight from Overweight at Barclays - TheFly
- 4 weeks ago - uniQure price target lowered to $48 from $65 at RBC Capital - TheFly
- 5 weeks ago - uniQure price target lowered to $31 from $46 at Goldman Sachs - TheFly
- 5 weeks ago - uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - PRNewsWire